Dominic Mazzocchi, MD
Internal Medicine · Point Pleasant Beach, NJNPI 1679546501
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 36.8% of the total. Reporting peaked in 2019 at $33,417 and has fallen 88.3% since, to $3,913 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,040 payments — averaging $48.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Amarin Pharma, Inc.$22K
- Johnson & Johnson$12K
- AstraZeneca$4K
- Novo Nordisk$4K
- GSK$3K
- plus $16K from 54 others
What the payments were for
- Consulting fees$6301%
- Speaking & faculty fees$57,32858%
- Travel & lodging$4,9455%
- Food & beverage$35,57036%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$21,364
- UBRELVY$19,565
- INVOKANA$10,239
- VRAYLAR$9,675
- QULIPTA$3,738
- FARXIGA$2,185
- BREZTRI$1,982
- TRINTELLIX$1,540
- FASENRA$1,112
- AIRSUPRA$1,092
- Ozempic$961
- RYBELSUS$711
- OFEV$630
- NURTEC ODT$485
- TRELEGY ELLIPTA$480
- AREXVY$375
- BREZTRI AEROSPHERE$336
- SYMBICORT$336
- BEVESPI AEROSPHERE$310
- XARELTO$250
How this compares
$98,552 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 118 | $230,301 |
| OzempicSemaglutide | 118 | $166,762 |
| JardianceEmpagliflozin | 118 | $133,550 |
| EliquisApixaban | 112 | $116,933 |
| FarxigaDapagliflozin Propanediol | 59 | $77,641 |
| AplenzinBupropion Hbr | 13 | $76,688 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $47,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $41,727 |
| VascepaIcosapent Ethyl | 51 | $37,977 |
| MyrbetriqMirabegron | 31 | $36,529 |
| VraylarCariprazine Hcl | 25 | $35,462 |
| TradjentaLinagliptin | 26 | $33,143 |
| XareltoRivaroxaban | 22 | $32,116 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $30,884 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $29,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $3,959 | $397,064236 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $2,605 | $195,881161 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $4,467 | $125,111119 claims |
| PfizerEliquis | $1,807 | $116,933112 claims |
| Bausch Health US, LLCAplenzin | $275 | $76,68813 claims |
| AbbVieVraylar, Linzess, Synthroid | $36,299 | $76,390271 claims |
| GSKTrelegy Ellipta | $2,921 | $41,72757 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $36,52931 claims |
| Johnson & JohnsonXarelto | $12,485 | $32,11622 claims |
| MerckJanuvia | $118 | $24,57623 claims |
| Lilly USA, LLCMounjaro, Trulicity | $796 | $24,05524 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $53 | $21,37014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Point Pleasant Beach
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.